In treating locally advanced unresectable NSCLC, administrating durvalumab, a PD-L1 inhibitor, has demonstrated a remarkable benefit in OS as a consolidation therapy post-chemoradiotherapy, as evidenced by the phase III PACIFIC trial where approximately half of the treated patients remained alive at the 4-year mark (53, 111). Here, CD274 is linked to non-small cell lung carcinoma.